UNSPSC 51151506: Esterase inhibitor

This classification denotes a cholinergic agonist with the molecular formula C8H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4ALN5933BH, chemically known as 1,2,5,6-tetrahydro-1-methylnicotinic acid, methyl ester but generally known as arecoline, which bears US NIH Compound Identifier 2230. arecoline most often comes in base, bromide, hydrobromide, hydrochloride, iodomethylate, methiodide, and p-stibonobenzoic acid forms. SMILES: CN1CCC=C(C1)C(=O)OC.

UNSPSC 51151506 Esterase inhibitor is a Commodity code that in recent state and local procurement encompasses naloxone and pharmaceutical products for community health and prescription management programs. State and local jurisdictions soliciting under this code include county health agencies and state health and human services departments. Seminole County, Florida procures naloxone and safe drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models that may involve pharmaceutical intermediaries and vendor capabilities in negotiated pricing and outcomes-based contracting. The scope of work reflects acquisition of naloxone products for overdose response and opioid-related public health interventions, as well as assessment of vendor capacity to manage state-level pharmacy benefit programs and direct pharmaceutical supply chains.

Recent opportunities show activity in Florida and Texas. Seminole County issued IFB60459723LAS on June 30, 2026, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the IFB response deadline was July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor information on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracting relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, with a response deadline of April 3, 2026. The Seminole County opportunity requires E-Verify compliance, drug-free workplace certification, standard insurance coverage, and includes a three-month probationary termination clause; the Texas RFI is preliminary market intelligence gathering and does not specify award values, set-asides, or binding procurement parameters.